Protagonist Therapeutics Inc (NASDAQ: PTGX)’s stock price has soared by 0.20 in relation to previous closing price of 45.82. Nevertheless, the company has seen a gain of 3.38% in its stock price over the last five trading days. accessnewswire.com reported 2025-05-21 that NEWARK, CA / ACCESS Newswire / May 21, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) today announced that Dinesh V. Patel, Ph.D.
Is It Worth Investing in Protagonist Therapeutics Inc (NASDAQ: PTGX) Right Now?
Protagonist Therapeutics Inc (NASDAQ: PTGX) has a price-to-earnings ratio of 60.35x that is above its average ratio. Additionally, the 36-month beta value for PTGX is 2.25. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 4 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for PTGX is 58.31M and currently, short sellers hold a 10.49% ratio of that float. The average trading volume of PTGX on May 23, 2025 was 1.27M shares.
PTGX’s Market Performance
The stock of Protagonist Therapeutics Inc (PTGX) has seen a 3.38% increase in the past week, with a -0.54% drop in the past month, and a 18.48% gain in the past quarter. The volatility ratio for the week is 1.94%, and the volatility levels for the past 30 days are at 2.43% for PTGX.. The simple moving average for the past 20 days is 2.80% for PTGX’s stock, with a 6.42% simple moving average for the past 200 days.
Analysts’ Opinion of PTGX
Many brokerage firms have already submitted their reports for PTGX stocks, with Goldman repeating the rating for PTGX by listing it as a “Neutral.” The predicted price for PTGX in the upcoming period, according to Goldman is $47 based on the research report published on December 06, 2024 of the previous year 2024.
BMO Capital Markets, on the other hand, stated in their research note that they expect to see PTGX reach a price target of $62. The rating they have provided for PTGX stocks is “Outperform” according to the report published on December 06th, 2024.
Wedbush gave a rating of “Outperform” to PTGX, setting the target price at $58 in the report published on November 05th of the previous year.
PTGX Trading at -1.65% from the 50-Day Moving Average
After a stumble in the market that brought PTGX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -24.24% of loss for the given period.
Volatility was left at 2.43%, however, over the last 30 days, the volatility rate increased by 1.94%, as shares surge +2.36% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.36% lower at present.
During the last 5 trading sessions, PTGX rose by +3.38%, which changed the moving average for the period of 200-days by +28.28% in comparison to the 20-day moving average, which settled at $44.66. In addition, Protagonist Therapeutics Inc saw 18.94% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PTGX starting from Ali Asif, who sale 1,756 shares at the price of $46.00 back on Apr 22 ’25. After this action, Ali Asif now owns 61,065 shares of Protagonist Therapeutics Inc, valued at $80,776 using the latest closing price.
Waddill William D., the Director of Protagonist Therapeutics Inc, sale 4,000 shares at $54.25 during a trade that took place back on Mar 17 ’25, which means that Waddill William D. is holding 13,130 shares at $217,000 based on the most recent closing price.
Stock Fundamentals for PTGX
Current profitability levels for the company are sitting at:
- 0.13 for the present operating margin
- 0.99 for the gross margin
The net margin for Protagonist Therapeutics Inc stands at 0.27. The total capital return value is set at 0.04. Equity return is now at value 8.99, with 8.19 for asset returns.
Based on Protagonist Therapeutics Inc (PTGX), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at 29.66.
Currently, EBITDA for the company is 252.84 million with net debt to EBITDA at -4.48. When we switch over and look at the enterprise to sales, we see a ratio of 13.08. The receivables turnover for the company is 7.67for trailing twelve months and the total asset turnover is 0.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.26.
Conclusion
In conclusion, Protagonist Therapeutics Inc (PTGX) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
